185
Participants
Start Date
March 30, 2020
Primary Completion Date
November 30, 2022
Study Completion Date
March 27, 2024
TTX-030, budigalimab and mFOLFOX6
Dose and schedule per protocol
TTX-030, budigalimab and docetaxel
Dose and schedule per protocol
TTX-030 and mFOLFOX6
Dose and schedule per protocol
TTX-030 and budigalimab
Dose and schedule per protocol
TTX-030, budigalimab, nab-paclitaxel and gemcitabine
Dose and schedule per protocol
TTX-030 and pembrolizumab
Dose and schedule per protocol
TTX-030, nab-paclitaxel and gemcitabine
Dose and schedule per protocol
Budigalimab and mFOLFOX6
Dose and schedule per protocol
National Cancer Center, Ilsandong-gu
Montefiore Medical Center, The Bronx
Seoul National University, Seongnam-si Bundan-gu
UPMC Hillman Cancer Center, Pittsburgh
Virginia Cancer Specialists, Fairfax
Prisma-Health Cancer Institute, Greenville
IACT Health - John B. Amos Cancer Center, Columbus
Orlando Health UF Health Cancer Center, Orlando
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami
Ocala Oncology Center PL, Ocala
Sarah Cannon Research Institute, Nashville
West Cancer Center and Research Institute, Germantown
Norton Cancer Institute, Louisville
University of Toledo, Toledo
University Hospitals Cleveland Medical Center, Cleveland
National Cancer Center, Seogu
Froedtert Hospital & Medical College of Wisconsin, Milwaukee
University of Chicago Medical Center, Chicago
Nebraska Cancer Center Oncology Hematology West P.C., Omaha
Ochsner Medical Center, New Orleans
NEXT Oncology, San Antonio
Hunstman Cancer Intitute, Salt Lake City
HonorHealth Research Institute, Scottsdale
University of Southern California, Los Angeles
Cedars-Sinai Medical Center, Los Angeles
UCLA Hematology/Oncology, Los Angeles
City of Hope Medical Center Clinical Trials Office, Duarte
Chao Family Comprehensive CC, UCI, Orange
UC Davis Comprehensive Cancer Center, Sacramento
Samsung Medical Center, Gangnam-gu
Severance Hospital Yonsei University, Seodaemun-gu
Asan Medical Center, Songpa-gu
Collaborators (1)
AbbVie
INDUSTRY
Trishula Therapeutics, Inc.
INDUSTRY